Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD22 + status confers therapeutic sensitivity to Inotuzumab ozogamicin in patients with Acute Lymphoid Leukemia.
This statement is based on a regulatory approval from the Health Canada:
BESPONSA (inotuzumab ozogamicin for injection) is indicated for monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).